1 / 37

HEARTLINE 2013 Genova 15/11/2013

HEARTLINE 2013 Genova 15/11/2013. Le cellule staminali ripareranno il cuore del Paziente infartuato? Lo studio STEMAMI OUTCOME. Dr Felice Achilli. 20 years ago ….Ejection Fraction in GISSI 1. (Volpi et al, Circulation 1993). 10 years ago ….not only EF!. Cardiac Remodeling Post AMI.

judith-pruitt
Télécharger la présentation

HEARTLINE 2013 Genova 15/11/2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HEARTLINE 2013 Genova 15/11/2013 Le cellule staminali ripareranno il cuore del Paziente infartuato? Lo studio STEMAMI OUTCOME Dr Felice Achilli

  2. 20 years ago ….Ejection Fraction in GISSI 1 (Volpi et al, Circulation 1993)

  3. 10 years ago ….not only EF!

  4. Cardiac Remodeling Post AMI Characteristic Normal LV Gp Remodeled Gp early Post MI (n = 31) (n=16) P value Q waves 24/31 13/16 NS Anterior wall 11/31 14/16 .007 Peak CK (u/L) 1910 ± 1046 4098 ± 2081 .006 ESV mL 40.6 ± 8.5 47.6 ± 8.4 .006 Ts-SD 33.7 ± 7.5 50.9 ± 10.8 <.0005 Te-SD 36.2 ± 20.2 45.2 ± 23.2 .048 EF% 53.1 ± 11.7 40.8 ± 7.6 <.0005 Infarct size 10.7 ± 5.9 26.4 ± 10.2 <.0005 Transmurality % 73.6 ± 17.3 85.7 ± 19.6 .039 ESV, end systolic volume; Ts-SD: Standard deviation of time to peak myocardial contraction Te-SD: Standard deviation of time to peak early relaxation Zhang Y, et al. Am Heart J 2008;156:1124-32.

  5. Today….. r < 3 h > 3 h ALL

  6. Tomorrow….: “Reverse Remodeling” or….

  7. Myocardial Recovery!

  8. “CARDIOMYOCITE RENEW” (MI) results in the loss of 1 billion functional cardiomyocytes, which are replaced with a fibrous scar, frequently leading to heart failure. Experimental data demonstrate that the mitotic renewal in the human myocardium exists but at a very low rate: 1% annually at the age of 25 and 0.45% at the age of 75. With this turnover rate, most cardiomyocytes will never be exchanged during a normal life span. Although the renewal rate may increase somewhat after injury, the heart itself is not able to effect large-scale cardiac regeneration.

  9. Cell Therapy of Cardiovascular Disease: start of CT Bone Marrow derived Cells Dimmler S., 2012 (with permission)

  10. CELL SOURCES TARGETED for CARDIAC REGENERATION • Evolution of the cell types used: • 1) Myoblasts • 2) Bone Marrow Derived Cells: • Hematopoetic stem cells • Mesenchymal stem cells • Endothelial progenitor cells • Side population cells FOURTH GENERATION : Cardiac Progenitors Cells (CPC) MORE THAN 2000 PATIENTS TREATED IN 10 YEARS!

  11. CELL THERAPHY AND ACUTE CORONARY DISEASES European Heart Journal (2012) Zimmet et Al.

  12. “EXOGENOUS CELL THERAPY” FOR CARDIAC REPAIR J.Tongers,D.W. Losordo, U.Landmesser EHJ 2011 Review (modif) Acute MI Chronic ICM C. Direct Endomyocardial cell injection

  13. “ENDOGENOUS CELL THERAPY” FOR CARDIAC REPAIR FGF family VEGF family (PIGF) EPO G-CSF/ GM-CSF SDF Growth Factors FLT-3 ligand Angiopoietin-1 HGF/IGF-1/GH

  14. CLINICAL BENEFIT Sanganalmat SK, et al., Basic Res Cardiol 2011

  15. CELLS THERAPY IN AMI: SAFETY NO DIFFERENCE ABOUT : IN STENT RESTENOSIS THROMBOSIS Re-AMI DEATH HOSPITALIZATION ARRYTHMIA SURGICAL REVASCULARIZATION Zimmet et Al. EHJ 2012

  16. META-ANALYSIS OF BMSC IN AMI PTS Follow-up 18m Follow-up 6m Zimmet et Al. EHJ 2012

  17. Changes in LVEF in Clinical Trial that have changed clinical practice based on effect on clinical outcome Postgrad Med J 2011; 87:558

  18. CRT for Patients With LV Dysfunction: A Systematic Review 4420 Pts Basal mean LVEF range, 21%-30% QRS duration (mean range, 155-209 milliseconds) NYHA 3 or 4 despite optimal pharmacotherapy. CRT improved LVEF 3.0%; (95% CI: 0.9%-5.1%), Mc Alister et al JAMA 2007

  19. TARGET ?

  20. PHASE 2 TRIALS IN CELL THERAPY: LIMITS • Smalls and monocentric studies • No randomization • Heterogeneous populations • No blinded study • Similar surrogate end-points but measured with • different methods (ECHO / MRI / SPECT )

  21. PHASE III CT aiming for approval of Cell Therapy

  22. Cell Therapy with CARDIAC stem cells

  23. Meta-analysis of G-CSF Trialsin AMI Pts Effect on EF at 6m of follow-up

  24. Hill J et al., Circulation, 2006 Abdel-Latif A, Am Heart J 2008

  25. STEM-AMI Trial 3 YEARS FOLLOW-UP Achilli F. et Al. Heart 2013 (submitted)

  26. STEM-AMI Trial: 3 YEARSFOLLOW-UP European Heart Journal (2012) Zimmet et Al.

  27. Time has come for hard clinical endpoints: GISSI Outliers STEM-AMI OUTCOME TRIAL • Large Phase III, open, randomized, multicenter nationwide Trial. • 1502 patients; 65 centres involved. • Anterior STEMI with low ejection fraction post PCI (<45%). • Symptoms-to-baloon time >3 h and <24 h • G-CSF (n=751) vs. saline (n=751) within 12 h from reperfusion. • Primary endpoint: Death, Recurrence of MI, Rehospitalisation for heart failure (accrural=2y; follow-up=3 y). E.C. APPROVAL MAY,8, 2013! FIRST PATIENT NOV,8,2013

  28. SWISS-AMI Trial

  29. TIME Trial

  30. EPO & G-CSF: dual protective mechanism after AMI ADAPTED FROM: NAGAI T, AM J PHYSIOL HEART CIRC PHYSIOL 2012

  31. Which growth factor for AMI?

  32. Large EPO clinical trials on STEMI

  33. Which determinants of success after AMI for the “dream growth factor”? • Extent of BMCs mobilization and homing • Characteristics of mobilized cells • Timing of therapy • Mobilization-independent effects • Patients characteristics

  34. Matrix Support Collagen Optimal timing ROS Inflammatory cytokines Adhesion Mobilization Migration Timing? 6 Optimal timing 5 4 Expression (fold increase estimate) 3 2 1 0 BL Day 3 Day 7 Day 14 Day 21-28 Martin_Rendon E et al., Eur Heart J 2008 Bartunek J et al. Nat Clin Pract Cardiovasc Med 2006

  35. Timing? Kuhlmann MT, et al. JEM 2006.

More Related